Fusen Pharmaceutical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Fusen Pharmaceutical hat ein Gesamteigenkapital von CN¥562.2M und eine Gesamtverschuldung von CN¥346.9M, wodurch sich der Verschuldungsgrad auf 61.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥1.3B bzw. CN¥781.5M. Fusen Pharmaceutical Das EBIT des Unternehmens beträgt CN¥21.5M, so dass der Zinsdeckungsgrad 1.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥34.8M.

Wichtige Informationen

61.7%

Verhältnis von Schulden zu Eigenkapital

CN¥346.86m

Verschuldung

Zinsdeckungsgrad	1.8x
Bargeld	CN¥34.85m
Eigenkapital	CN¥562.23m
Gesamtverbindlichkeiten	CN¥781.52m
Gesamtvermögen	CN¥1.34b

Jüngste Berichte zur Finanzlage

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Dec 14

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Sep 02

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Apr 02

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

Mar 06

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 1652Die kurzfristigen Aktiva des Unternehmens (CN¥566.8M) decken seine kurzfristigen Passiva (CN¥664.5M) nicht.

Langfristige Verbindlichkeiten: 1652Die kurzfristigen Vermögenswerte des Unternehmens (CN¥566.8M) übersteigen seine langfristigen Verbindlichkeiten (CN¥117.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 1652Die Nettoverschuldung im Verhältnis zum Eigenkapital (55.5%) wird als hoch angesehen.

Schulden abbauen: 1652Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 30.8% auf 61.7% gestiegen.

Schuldendeckung: 1652Der operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: 1652Die Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (1.8x Deckung) nicht gut gedeckt.

Fusen Pharmaceutical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Recent updates

New minor risk - Market cap size

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021)

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

CEO & Executive Director recently bought HK$375k worth of stock

Executive Chairman recently bought HK$791k worth of stock

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Executive Chairman recently bought HK$2.3m worth of stock

Less than half of directors are independent

CEO & Executive Director recently bought HK$2.2m worth of stock

Executive Chairman recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$658k worth of stock

CEO & Executive Director recently bought HK$79k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021)

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022

CEO & Executive Director recently bought HK$157k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$856k worth of stock

CEO & Executive Director recently bought HK$2.1m worth of stock

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019)

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019)

Investor sentiment improved over the past week

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

New 90-day low: HK$4.17

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Company Secretary has left the company

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Market bids up stock over the past week

New 90-day high: HK$6.00

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Market bids up stock over the past week